Hospital
Ascension Sacred Heart Emerald Coast
Ascension Sacred Heart Emerald Coast was paid $11.93M by Medicaid between Jan 2018 and Nov 2024, across 158 billing codes. Its largest line is 92507, Treatment of speech, language, voice, communication, and/or auditory processing disorder — 32% of everything it billed.
33Billing provider infoASCENSION SACRED HEART EMERALD COAST
MIRAMAR BEACH, FL 32550
MIRAMAR BEACH, FL 32550
33aNPI1558391771assigned 07/04/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$11.93M
24GClaims271,507
24DCodes billed158
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#43 of 163
Median peer was paid$4.77M
This provider vs. median2.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 21,024 | $501K | |
| 2019 | 56,180 | $1.99M | |
| 2020 | 50,117 | $1.85M | |
| 2021 | 59,668 | $2.48M | |
| 2022 | 59,761 | $3.14M | |
| 2023 | 20,483 | $1.40M | |
| 2024incomplete | 4,274 | $573K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 32% | 22,262 | 6,639 | $3.81M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 11% | 13,233 | 4,309 | $1.26M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.1% | 8,709 | 7,596 | $1.08M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 8.4% | 8,584 | 2,950 | $1.00M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.9% | 7,591 | 7,044 | $939K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.5% | 6,991 | 5,817 | $653K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.1% | 1,470 | 1,305 | $246K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.0% | 1,452 | 1,243 | $237K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.6% | 2,116 | 1,756 | $195K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.5% | 2,015 | 1,879 | $174K |
| 36415 | Collection of venous blood by venipuncture | 1.3% | 7,557 | 6,233 | $157K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.0% | 579 | 500 | $123K |
146 more codes
| 80053 | Comprehensive metabolic panel | 1.0% | 13,377 | $123K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 1,115 | $110K |
| 92523 | <1% | 619 | $89K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 6,949 | $78K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 522 | $67K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 230 | $66K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 872 | $64K |
| 97168 | <1% | 400 | $64K | |
| A9270 | Non-covered item or service | <1% | 2,277 | $62K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 4,459 | $59K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 781 | $58K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 16,624 | $53K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,133 | $51K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,905 | $44K |
| 81001 | <1% | 7,754 | $37K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,802 | $32K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,044 | $30K |
| 97161 | <1% | 151 | $30K | |
| 87653 | <1% | 1,233 | $29K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,635 | $29K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,145 | $27K |
| 81003 | <1% | 3,145 | $27K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,935 | $27K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,206 | $27K |
| 87634 | <1% | 1,264 | $26K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 617 | $25K |
| 97165 | <1% | 155 | $25K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 359 | $24K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,495 | $22K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,849 | $22K |
| 84484 | <1% | 2,862 | $22K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,611 | $21K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,792 | $21K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,624 | $21K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 948 | $20K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 796 | $20K |
| 83735 | <1% | 3,273 | $18K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,157 | $17K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,101 | $17K |
| 76801 | <1% | 678 | $16K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 151 | $14K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 327 | $14K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 119 | $14K |
| 82962 | <1% | 1,249 | $13K | |
| 86762 | <1% | 370 | $12K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,113 | $12K |
| 87070 | <1% | 239 | $12K | |
| 85027 | <1% | 1,494 | $11K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,416 | $11K |
| 83690 | <1% | 4,199 | $11K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,788 | $11K |
| 86850 | <1% | 1,266 | $11K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,642 | $10K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 49 | $10K |
| 96376 | <1% | 1,602 | $10K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,824 | $10K |
| 85610 | <1% | 1,393 | $10K | |
| 01999 | <1% | 1,926 | $10K | |
| 84703 | <1% | 3,097 | $10K | |
| 86900 | <1% | 2,353 | $9K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,257 | $9K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,731 | $9K |
| 83880 | <1% | 1,302 | $8K | |
| 97164 | <1% | 68 | $8K | |
| 86140 | <1% | 2,600 | $8K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,214 | $8K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,803 | $8K |
| 84439 | <1% | 643 | $8K | |
| G0378 | Hospital observation service, per hour | <1% | 331 | $8K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,596 | $8K |
| 87077 | <1% | 1,570 | $6K | |
| 97162 | <1% | 46 | $6K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 28 | $6K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 450 | $6K |
| 86901 | <1% | 2,351 | $6K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 711 | $5K |
| 92526 | <1% | 139 | $5K | |
| J3490 | Unclassified drugs | <1% | 219 | $4K |
| 80061 | Lipid panel | <1% | 1,238 | $4K |
| 87040 | <1% | 802 | $4K | |
| 83605 | <1% | 586 | $4K | |
| 87186 | <1% | 920 | $4K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,321 | $4K |
| 84702 | <1% | 1,444 | $4K | |
| 82728 | <1% | 193 | $3K | |
| 80076 | <1% | 409 | $3K | |
| 85730 | <1% | 646 | $3K | |
| 73610 | <1% | 44 | $2K | |
| 93971 | <1% | 30 | $2K | |
| 86803 | <1% | 775 | $2K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 26 | $2K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 565 | $2K |
| 99234 | <1% | 59 | $2K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 47 | $2K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 588 | $2K |
| 76641 | <1% | 40 | $1K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 718 | $1K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 282 | $1K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 64 | $1K |
| 82950 | <1% | 462 | $1K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 64 | $1K |
| 87340 | <1% | 630 | $1K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 54 | $1K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 46 | $1K |
| 87486 | <1% | 30 | $1K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 79 | $1K |
| 74018 | <1% | 59 | $905.37 | |
| 83540 | <1% | 258 | $897.70 | |
| 85379 | <1% | 399 | $848.13 | |
| 82570 | <1% | 1,023 | $842.34 | |
| 85652 | <1% | 586 | $827.68 | |
| 82607 | <1% | 137 | $706.19 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 179 | $667.11 |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 42 | $646.63 |
| 73630 | <1% | 70 | $589.55 | |
| 84156 | <1% | 859 | $505.21 | |
| 76830 | Ultrasound, transvaginal | <1% | 15 | $454.93 |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 381 | $435.18 |
| 84112 | <1% | 29 | $364.22 | |
| 82565 | <1% | 58 | $358.40 | |
| 73030 | <1% | 14 | $258.75 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 203 | $234.23 |
| 84550 | <1% | 660 | $229.97 | |
| 83615 | <1% | 670 | $225.60 | |
| 82550 | <1% | 50 | $223.70 | |
| 87210 | <1% | 732 | $216.07 | |
| 84466 | <1% | 136 | $123.31 | |
| 86592 | <1% | 734 | $117.07 | |
| 87581 | <1% | 30 | $51.13 | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 30 | $51.13 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 941 | $50.48 |
| 84450 | <1% | 52 | $25.71 | |
| 84460 | <1% | 50 | $25.71 | |
| 73564 | <1% | 32 | $25.13 | |
| 82746 | <1% | 32 | $17.24 | |
| 84520 | <1% | 43 | $13.80 | |
| 83550 | 0% | 124 | $0.00 | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | 0% | 13 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 70 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 82 | $0.00 |
| D9420 | 0% | 88 | $0.00 | |
| 3044F | 0% | 61 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 79 | $0.00 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 0% | 51 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 125 | $0.00 |
| 81025 | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCORNEJO, COBA (COO)
| Provider | Location | Paid |
|---|---|---|
| Sacred Heart Health System, INC. | Pensacola, FL | $38.49M |
| Ascension Sacred Heart Gulf | Port St Joe, FL | $2.50M |
| ST Vincents Health System INC | St. Johns, FL | $24K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.